Esperion Therapeutics, Inc. (ESPR) focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Its Bempedoic acid, market name Nexletol, along with its sister medication Nexlizet (a combination of Bempedoic acid and ezetimibe) were recently approved by the FDA. The medication was then approved by the European Commission for sale in the EU area.
Bempedoic acid is a new class of cholesterol-lowering drug. I don’t pretend to understand the science. The mechanism of action is described by the company here. In my layman’s terms,